MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
Saved in:
Main Authors: | Lucia Y. Chen, Santiago Thibaud, Saoirse Bodnar, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J. Sanchez, Cesar Rodriguez, Adriana C. Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Blood Advances |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924006578 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
by: Zachary M. Avigan, et al.
Published: (2025-01-01) -
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01) -
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01) -
Rare e14a3 (b3a3) BCR-ABL Fusion in Chronic Myeloid Leukemia in India: The Threats and Challenges in Monitoring Minimal Residual Disease (MRD)
by: Salil Vaniawala, et al.
Published: (2013-01-01) -
The Last and Latest Dickens
by: Clotilde De Stasio
Published: (2012-01-01)